Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed written informed consent granted before undertaking any study-specific procedures;
- Male or female patient ≥18 years of age on the day of consenting to the study;
- Histologically or cytologically confirmed diagnosis of solid cancer;
At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with following characteristics:
- a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest axis, or
- a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;
- Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2;
Patient from one the following categories:
- Patient for whom no standard therapy exists, or standard therapy is contraindicated, or
- Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy, immunological treatment, surgery) which will start after completion of at least one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.
Exclusion Criteria:
- Known hypersensitivity to any of the excipients in the NZ-DTX Depot formulation (docetaxel, calcium sulphate, sodium carboxymethylcellulose);
- Life expectancy <3 months;
- Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at increased risk of clinically significant bleeding, in the judgement of the Investigator. If the patient has an international normalised ratio (INR) below 1.2 the Investigator may judge if interruption of anticoagulant therapy is warranted;
Any of the following abnormal laboratory values at screening;
Bone marrow function:
- Absolute neutrophil count (ANC) <1.5 x 109/l;
- Platelet count <100 x 109/l;
- Haemoglobin <9.0 mg/dl.
Coagulation:
- International Normalized Ratio (INR) >1.2.
Hepatic, renal, and biochemistry parameters:
- Aspartate transaminase (AST) or alanine transaminase (ALT) >2.5 x upper limit of normal (ULN) (>5 x ULN if liver metastases present)*;
- Alkaline phosphatase (ALP) >2.5 x ULN;
- Total bilirubin >1.5 x ULN;
Estimated glomerular filtration rate (eGFR) <40 ml/min/1.73 m² using the Modified Cockcroft & Gault formula.
- For patients with liver impairment who have serum transaminase levels (ALT and/or AST) greater than 1.5 times x ULN - the doses will be restricted to max. 75mg/m2. In the event this is not possible the patient will not be included.
- Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion or ascites;
- Clinically significant heart disease (i.e. heart failure or myocardial infarction within 6 months of screening, instable angina pectoris);
- History of thromboembolic or cerebrovascular events within 6 months of screening;
- Major surgery within 2 weeks of screening, or patient not recovered from major surgery;
- Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of screening;
- Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments, excepting alopecia;
- Concurrent participation in another investigational study;
- Last investigational drug administration in a prior investigational study within 14 days of study treatment initiation or <5 times the half-life of the investigational drug, whichever is longer;
- Last administration of other anti-neoplastic drug within 14 days of study treatment initiation;
- Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX Depot, or irradiated lesion to be injected without signs of disease progression since irradiation;
- For men and women of childbearing potential: Unwillingness to follow contraception requirements;
- Female patients with planned or current pregnancy and/or currently breastfeeding;
- Any other severe, acute or chronical medical or psychiatric condition or laboratory abnormality that, in the judgement of the Investigator, would make the patient inappropriate for study participation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:NZ-DTX Depot
|
Docetaxel in NanoZolid formulation, for intratumoural injection
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.
時間枠:5 weeks
|
The MTD will be determined by incidence of DLTs
|
5 weeks
|
|
The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.
時間枠:5 weeks
|
The RP2D will be determined by frequency and severity of adverse events
|
5 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot
時間枠:5 weeks
|
Frequency and severity of treatment-emergent adverse events
|
5 weeks
|
|
Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot
時間枠:5 weeks
|
Plasma concentration of docetaxel
|
5 weeks
|
|
Anti-tumour effect following an intratumoural injection of NZ-DTX Depot
時間枠:5 weeks
|
Tumour response by RECIST
|
5 weeks
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Presence of immune biomarkers in plasma, following an intratumoural injection of NZ-DTX Depot
時間枠:9 weeks
|
Analysis of cytokines in plasma
|
9 weeks
|
|
Presence of immune biomarkers in tissue, following an intratumoural injection of NZ-DTX Depot
時間枠:9 weeks
|
Immunohistochemistry analysis [PD-L1] in tissue
|
9 weeks
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Charlotta Gauffin, PhD、Lidds AB
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NZ-DTX-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。